
Meeting Notes: Interagency Meeting (FDA, EPA, CDC, NIH, BARDA) with Oxitec/Intrexon May 17, 2017



Ex. 5 - Deliberative Process

EPA, FDA and Oxitec discussed paths forward, given the regulatory options:

Ex. 5 - Deliberative Process

Post-meeting Notes: Next Steps per Oxitec/Intrexon from the company's feedback on Mon May 22:

Ex. 5 - Deliberative Process

[PAGE * MERGEFORMAT]